TMDX Stock Risk & Deep Value Analysis
Transmedics Group Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About TMDX Stock
We analyzed Transmedics Group Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TMDX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
TMDX Risk Analysis & Red Flags
What Could Go Wrong
The Johnson Fistel investigation, announced on June 12, 2026, regarding disclosures concerning margin pressure and NOP investments, could escalate. If this leads to a formal SEC inquiry or significant legal action, it might result in substantial fines (potentially tens of millions of dollars) and reputational damage, potentially impacting the successful rollout of the NOCS program's profitability and future contract acquisitions beyond 2027.
Risk Matrix
Overall
Aggressive
Financial
Medium-High
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Medium-High
Red Flags
- ⚠
Q1 2026 EPS of $0.30 significantly missed consensus estimates of $0.62, highlighting immediate profitability pressures.
- ⚠
Johnson Fistel's investigation regarding margin pressure and NOP investments signals potential legal/regulatory scrutiny over financial disclosures or operational investments.
- ⚠
Reliance on substantial, high-risk capital investments (22 owned aircraft) for NOCS, impacting near-term profitability without guaranteed long-term returns.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (estimated July 30, 2026): If Q2 revenue or EPS falls below consensus estimates, indicating continued operational challenges or slower NOCS ramp, potentially causing a significant stock price decline.
- 📅
Johnson Fistel Investigation Escalation (ongoing): If the investigation leads to formal charges, SEC action, or a significant class-action lawsuit, potentially resulting in substantial financial penalties or regulatory restrictions on NOCS operations.
When to Reconsider
- 🚪
Exit if quarterly revenue growth decelerates to below 15% YoY for two consecutive quarters, indicating a slowdown in NOCS adoption or OCS sales.
- 🚪
Sell if operating margins (which were 7.6% YoY previously) fall below 5% for two consecutive quarters, signaling unsustainable cost structures or failed NOCS leverage.
- 🚪
Exit if the Johnson Fistel investigation results in a formal SEC enforcement action or a significant class-action lawsuit with estimated liabilities exceeding $100 million.
Unlock TMDX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Transmedics Group Inc (TMDX) Do?
Market Cap
$2.54B
Sector
Healthcare
Industry
Medical Devices
Employees
728
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Visit Transmedics Group Inc WebsiteInvestment Thesis
If TransMedics can successfully scale its unique National Organ Care System (NOCS) program, leveraging its proprietary OCS technology and dedicated air fleet to significantly increase organ utilization and reduce discard rates, demonstrating clear operating margin expansion and consistent revenue growth from this integrated service by late 2027, then the market will re-rate TMDX from a medical device company with logistics costs to a high-growth, high-margin, essential medical infrastructure provider, justifying a significantly higher valuation multiples. This is bullish because the current market valuation (low trailing P/E and recent stock performance) appears to be overly focused on near-term profitability pressures and recent legal scrutiny, underappreciating the long-term, disruptive potential and market leadership of the NOCS platform.
Is TMDX Stock Undervalued?
Unlock the full AI analysis for TMDX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TMDX Price Targets & Strategy
12-Month Target
$88.00
Bull Case
$105.00
Bear Case
$60.00
Valuation Basis
40x forward P/E on estimated FY2027 EPS of $2.20 (reflecting ~82% analyst-projected growth from current run-rate).
Entry Strategy
Dollar-cost average between $68-$72, targeting entries near key support levels or if the Johnson Fistel investigation offers clarity, avoiding substantial downside on further negative news.
Exit Strategy
Take initial profits at $88 (12-month target), scale out further at $100+. Implement a stop-loss order if the stock breaks below $65 (key psychological support and recent lows).
Portfolio Allocation
5% for moderate risk tolerance
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is TMDX Financially Healthy?
Valuation
P/E Ratio
14.79
Forward P/E
36.56
EV/EBITDA
3.86
PEG Ratio
0.14
Price/Book
5.23
Price/Sales
7.60
Profitability
Gross Margin
59.09%
Operating Margin
14.85%
Net Margin
27.04%
Return on Equity
41.92%
Revenue Growth
30.24%
EPS
$4.23
Balance Sheet
Current Ratio
7.14
Quick Ratio
6.41
Debt/Equity
1.08
Other
Beta (Volatility)
1.91
Does TMDX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
TransMedics' moat is strengthening as its OCS technology gains wider adoption and, more significantly, as its NOCS network scales. The capital intensity and regulatory hurdles associated with building and operating an integrated organ logistics system create substantial barriers to entry, making it difficult for new competitors to replicate its end-to-end solution for at least 10-15 years.
Moat Erosion Risks
- •Failure of NOCS to achieve projected utilization and cost efficiencies, making the capital-intensive infrastructure unprofitable.
- •Development of superior, less capital-intensive organ preservation or transportation technologies by competitors.
- •Significant regulatory changes or unfavorable reimbursement policies for integrated organ logistics services.
TMDX Competitive Moat Analysis
Sign up to see competitive advantages
TMDX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - a mix of enthusiasm for the transformative NOCS vision and concern over recent earnings misses and legal investigation.
Institutional Sentiment
Neutral - high expected next-year EPS growth suggests underlying analyst confidence, but recent Q1 miss and investigation likely temper any upgrades or new bullish coverage.
Insider Activity (Form 4)
Directors David Weill and James R. Tobin each received RSU grants of 2,922 shares on May 20, 2026. These were equity awards and not open-market buy/sell transactions. No open-market CEO/CFO activity identified in the last 90 days.
Options Flow
Normal options activity (no specific unusual options activity or significant directional bias indicated in the provided data).
Earnings Intelligence
Next Earnings
2026-07-30
Surprise Probability
Medium
Historical Earnings Pattern
Mixed, with a significant Q1 2026 EPS miss against consensus but prior strong growth phases. Market reaction will likely be highly sensitive to margin improvements and NOCS progress.
Key Metrics to Watch
Competitive Position
Top Competitor
XVIVO Perfusion AB
Market Share Trend
Gaining ground, particularly in the integrated organ logistics segment with the NOCS program, challenging traditional fragmented models.
Valuation vs Peers
Trading at a trailing P/E of 16.73, which is relatively low for a company with such high projected next-year EPS growth (82.32%), suggesting it is currently discounted due to profitability concerns and the recent investigation.
Competitive Advantages
- •Proprietary Organ Care System (OCS) technology for organ preservation
- •Integrated National Organ Care System (NOCS) network, including dedicated air fleet
- •First-mover advantage in comprehensive organ logistics solutions
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive TMDX Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (estimated July 30, 2026): Positive surprise on revenue or operating margin expansion, or a significant update on NOCS utilization rates for hearts and livers, could re-rate shares.
- •Resolution/Clarification of Johnson Fistel Investigation (Q3/Q4 2026): A positive outcome or clear dismissal of the investigation's concerns could alleviate regulatory overhang.
Medium-Term (6-18 months)
- •NOCS Expansion into New Organ Types (mid-2027): Successful FDA approval and commercial launch for lungs or kidneys via NOCS, potentially adding $100M+ in annual revenue run-rate.
- •NOCS Network Optimization & Cost Efficiencies (late 2027-early 2028): Demonstrable improvements in operating margins driven by increased scale and utilization of the existing 22 aircraft fleet.
Long-Term (18+ months)
- •Global Organ Transplantation Market Dominance (2028-2029): If NOCS establishes a dominant position in major international markets beyond the US, capturing >50% market share in integrated logistics, enabling sustained annual revenue growth above 20% and significant free cash flow generation.
- •Technological Leap in Organ Viability (2029-2030): Introduction of next-generation OCS technology extending organ preservation times beyond 24 hours, dramatically increasing the addressable market and enabling complex cross-continental transplants.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for TMDX?
- ✓
Watch quarterly NOCS revenue contribution and gross margin trend — acceleration towards 50%+ gross margin on NOCS services would validate the model.
- ✓
Monitor balance sheet for increases in net debt or significant cash burn exceeding current cash position of ~$461.7M, indicating funding issues for NOCS expansion.
- ✓
Any positive news or formal dismissal regarding the Johnson Fistel investigation.
Bull Case Analysis
Sign up free to see the bull case
Competing with TMDX
See how Transmedics Group Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Transmedics Group Inc TMDX | $2.5B | 6.8 | 14.8 | — | 27.0% | 30.2% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Transmedics Group Inc Makes Money
TransMedics Group Inc. operates at the forefront of organ transplantation by developing and commercializing the Organ Care System (OCS), a portable technology that maintains donor organs in a near-physiologic state outside the body. This extends viability and expands the window for successful transplantation. Building on this technology, TransMedics has developed the National Organ Care System (NOCS), an integrated, nationwide logistics and clinical support platform, which includes its own fleet of 22 aircraft. This allows the company to manage the entire organ transplant process, from donor retrieval to recipient implantation, aiming to significantly increase the utilization of donor organs and improve patient outcomes.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Transmedics Group Inc (TMDX)?
As of June 12, 2026, Transmedics Group Inc has a DVR Score of 6.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Transmedics Group Inc?
Transmedics Group Inc's market capitalization is approximately $2.5B. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Transmedics Group Inc use?
TMDX is the ticker symbol for Transmedics Group Inc. The company trades on the NGM.
What is the risk level for TMDX stock?
Our analysis rates Transmedics Group Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of TMDX?
Transmedics Group Inc currently has a price-to-earnings (P/E) ratio of 14.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Transmedics Group Inc's revenue growing?
Transmedics Group Inc has reported revenue growth of 30.2%. The company is showing strong top-line momentum.
Is TMDX stock profitable?
Transmedics Group Inc has a profit margin of 27.0%. This indicates strong profitability.
How often is the TMDX DVR analysis updated?
Our AI-powered analysis of Transmedics Group Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TMDX (Transmedics Group Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.